No headlines found.
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
Globe Newswire (Wed, 6-Mar 1:20 PM ET)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, JNPR, INBX, RYZB
PRNewswire (Mon, 12-Feb 8:30 PM ET)
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm
PRNewswire (Mon, 12-Feb 1:43 PM ET)
Business Wire (Sat, 10-Feb 11:23 AM ET)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGAN
Globe Newswire (Sat, 10-Feb 10:51 AM ET)
Kuehn Law Encourages PGTI, AMAM, JNPR, and GLT Investors to Contact Law Firm
Globe Newswire (Thu, 8-Feb 12:26 PM ET)
INVESTIGATION ALERT: Halper Sadeh LLC Investigates PGTI, FGH, AMAM
Globe Newswire (Tue, 6-Feb 9:26 PM ET)
INVESTIGATION ALERT: Halper Sadeh LLC Investigates AXNX, AMAM, FGH
PRNewswire (Tue, 6-Feb 10:32 AM ET)
PRNewswire (Mon, 5-Feb 8:32 PM ET)
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RYZB, FGH, AXNX, AMAM
PRNewswire (Mon, 29-Jan 11:02 PM ET)
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Ambrx Biopharma trades on the NASDAQ stock market under the symbol AMAM.
As of March 28, 2024, AMAM stock price was flat at $28.00 with million shares trading.
AMAM has a beta of 1.87, meaning it tends to be more sensitive to market movements. AMAM has a correlation of 0.03 to the broad based SPY ETF.
AMAM has a market cap of $1.77 billion. This is considered a Small Cap stock.
Last quarter Ambrx Biopharma reported $53,000 in Revenue and -$.37 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.28.
The top ETF exchange traded funds that AMAM belongs to (by Net Assets): VTI.
AMAM has outperformed the market in the last year with a return of +207.4%, while the SPY ETF gained +33.6%. In the last 3 month period, AMAM beat the market returning +90.5%, while SPY returned +10.1%. However, in the most recent 2 weeks AMAM has underperformed the stock market by returning 0.0%, while SPY returned +1.7%.
AMAM support price is $27.99 and resistance is $28.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMAM stock will trade within this expected range on the day.